In preclinical Multiple Sclerosis, GLX markers are increased in the blood days before symptoms debuted. Immune cells may have removed the GLX before the entering the CNS, causing harm. Early diagnosis and prediction of autoimmune attacks may be possibly with GLX Signature monitoring.